Universal Implementation of Newborn Screening in India

Newborn screening is a successful program in many developed countries. In India, the benefits of dried blood spot screening have been recognized and that screening is slowly gaining traction. There are significant issues standing in the way of universal implementation of a newborn screening program...

Full description

Bibliographic Details
Main Author: Thomas Mookken
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:International Journal of Neonatal Screening
Subjects:
Online Access:https://www.mdpi.com/2409-515X/6/2/24
id doaj-606f2498e7ae492db6e9a26a6a3dd694
record_format Article
spelling doaj-606f2498e7ae492db6e9a26a6a3dd6942020-11-25T02:10:02ZengMDPI AGInternational Journal of Neonatal Screening2409-515X2020-03-01622410.3390/ijns6020024ijns6020024Universal Implementation of Newborn Screening in IndiaThomas Mookken0NeoGen Labs, UCF Center, 84/3 Oil Mill Road, Lingararajpuram, Bengaluru 560 084, Karnataka, IndiaNewborn screening is a successful program in many developed countries. In India, the benefits of dried blood spot screening have been recognized and that screening is slowly gaining traction. There are significant issues standing in the way of universal implementation of a newborn screening program in India: awareness, cost, advocacy, public policy, and politics. Three regional screening programs, Chandigarh, Goa, and Kerala could serve as models for other programs in India. The data for this commentary were based on personal experiences from managing public newborn screening programs, searches on PubMed and Google, and personal interactions with experts in the field. The overwhelming recommendation is to universally screen for congenital hypothyroidism in India, because it is easy and inexpensive to treat, with excellent outcomes. It would also be beneficial to consider screening universally for glucose-6-phosphate dehydrogenase deficiency due to its high incidence and ease of treatment. Finally, sickle cell disease should be screened in those areas in India where it is prevalent due to the costs associated with universal screening. Achieving universal screening is a challenge, and it is very difficult to predict when every baby born in India will be screened for at least congenital hypothyroidism.https://www.mdpi.com/2409-515X/6/2/24inborn errors of metabolismneonatalnewborn screeningpopulation screeningsickle cell disease
collection DOAJ
language English
format Article
sources DOAJ
author Thomas Mookken
spellingShingle Thomas Mookken
Universal Implementation of Newborn Screening in India
International Journal of Neonatal Screening
inborn errors of metabolism
neonatal
newborn screening
population screening
sickle cell disease
author_facet Thomas Mookken
author_sort Thomas Mookken
title Universal Implementation of Newborn Screening in India
title_short Universal Implementation of Newborn Screening in India
title_full Universal Implementation of Newborn Screening in India
title_fullStr Universal Implementation of Newborn Screening in India
title_full_unstemmed Universal Implementation of Newborn Screening in India
title_sort universal implementation of newborn screening in india
publisher MDPI AG
series International Journal of Neonatal Screening
issn 2409-515X
publishDate 2020-03-01
description Newborn screening is a successful program in many developed countries. In India, the benefits of dried blood spot screening have been recognized and that screening is slowly gaining traction. There are significant issues standing in the way of universal implementation of a newborn screening program in India: awareness, cost, advocacy, public policy, and politics. Three regional screening programs, Chandigarh, Goa, and Kerala could serve as models for other programs in India. The data for this commentary were based on personal experiences from managing public newborn screening programs, searches on PubMed and Google, and personal interactions with experts in the field. The overwhelming recommendation is to universally screen for congenital hypothyroidism in India, because it is easy and inexpensive to treat, with excellent outcomes. It would also be beneficial to consider screening universally for glucose-6-phosphate dehydrogenase deficiency due to its high incidence and ease of treatment. Finally, sickle cell disease should be screened in those areas in India where it is prevalent due to the costs associated with universal screening. Achieving universal screening is a challenge, and it is very difficult to predict when every baby born in India will be screened for at least congenital hypothyroidism.
topic inborn errors of metabolism
neonatal
newborn screening
population screening
sickle cell disease
url https://www.mdpi.com/2409-515X/6/2/24
work_keys_str_mv AT thomasmookken universalimplementationofnewbornscreeninginindia
_version_ 1724921065352724480